Abstract
Guidelines on the treatment of metastatic squamous cell carcinoma of the penis are limited to a few prospective trials. Cisplatin-based regimens represent the standard of treatment with promising activity of taxanes. Recently, epidermal growth factor receptor overexpression has been shown in these patients. We treated an elderly man with a docetaxel-cetuximab combination after failure of the cisplatin regimen. We observed a necrosis of the inguinal lymph nodes and a reduction of (18)F-fluorodeoxyglucose uptake at PET/CT scan. Only mild mucositis and skin toxicity had been detected. Our case report, the first in the literature, shows that this combination is active and well tolerated in penile squamous cell carcinoma.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / administration & dosage
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carcinoma, Squamous Cell / diagnostic imaging
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / pathology
-
Cetuximab
-
Docetaxel
-
Drug Administration Schedule
-
Fluorodeoxyglucose F18
-
Humans
-
Male
-
Penile Neoplasms / diagnostic imaging
-
Penile Neoplasms / drug therapy*
-
Penile Neoplasms / pathology
-
Positron-Emission Tomography
-
Taxoids / administration & dosage
-
Taxoids / therapeutic use
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Taxoids
-
Fluorodeoxyglucose F18
-
Docetaxel
-
Cetuximab